Results 191 to 200 of about 2,969,444 (397)

Deep Transfer Learning for Breast Cancer Classification [PDF]

arXiv
Breast cancer is a major global health issue that affects millions of women worldwide. Classification of breast cancer as early and accurately as possible is crucial for effective treatment and enhanced patient outcomes. Deep transfer learning has emerged as a promising technique for improving breast cancer classification by utilizing pre-trained ...
arxiv  

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

Clinical Cancer Research, 2004
T. Nielsen, Forrest D. Hsu, Kristin Jensen, Maggie C. U. Cheang, G. Karaca, Zhiyuan Hu, T. Hernandez-Boussard, C. Livasy, D. Cowan, L. Dressler, L. Akslen, J. Ragaz, A. Gown, C. Gilks, M. van de Rijn, C. Perou   +15 more
semanticscholar   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling. [PDF]

, 2015
Matriptase is an epithelia-specific membrane-anchored serine protease that has received considerable attention in recent years because of its consistent dysregulation in human epithelial tumours, including breast cancer.
Bergum, Christopher, Boerner, Julie, Colombo, Éloïc, Lang, Julie E, Leduc, Richard, List, Karin, Marsault, Eric, Molinolo, Alfredo A, Murray, Andrew S, Tanabe, Lauren M, Varela, Fausto A, Zoratti, Gina L   +11 more
core   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Clinicopathologic significance of heat shock protein 60 as a survival predictor in breast carcinoma

Frontiers in Oncology
BackgroundWhile Heat Shock Protein 60 (HSP60) has been linked to human tumor, its clinic significance specifically in breast carcinoma is unclear. This investigation aims to retrospectively evaluate how HSP60 protein levels relate to survival outcomes ...
Qing Wang, Shengzhou Chen, Zhihong Wu, Jungang Ni   +3 more
doaj   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Sydney Conservatorium of Music Postgraduate Handbook 2009 [PDF]

, 2009
In stage III breast carcinoma, metastasized disease needs to be determined. In the past, conventional imaging by liver ultrasound, chest X-ray and bone scintigraphy was the work-up of choice.
Baas, I.O., Bulten, B.F., Haas, M.J. de, Klerk, J.M. de, Ooijen, B. van, Rodenburg, C.J.   +5 more
core